Liran Shlush

Liran Shlush

Auto-generated profile, based on publicly available information

Liran Shlush

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2018 in Nature
Verified
Journal Article
Open access
PDF file
SASagi Abelson
Sagi Abelson
GCGrace Collord
Grace Collord
SNStanley W. K. Ng
Stanley W. K. Ng
OWOmer Weissbrod
Omer Weissbrod
NCNetta Mendelson Cohen
Netta Mendelson Cohen
LSLiran I. Shlush
Liran I. Shlush
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure1. The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion2,3. However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH)4,5,6,7,8. Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age- and gender-matched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.

12 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NZN. Zioni
N. Zioni
ABA. Akhiad Bercovich
A. Akhiad Bercovich
NCN. Chapal-Ilani
N. Chapal-Ilani
TBTal Bacharach
Tal Bacharach
NRN. Rappoport
N. Rappoport
LSLiran I. Shlush
Liran I. Shlush
Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in self-renewal can be detected in both human and rodent DNMT3AMut-HSCs when exposed to FBM. DNMT3AMut-HSCs derived from older mice interacting with FBM have even higher self-renewal in comparison to DNMT3AMut-HSCs derived from younger mice. Single cell RNA-sequencing on rodent HSCs after exposing them to FBM reveal a 6-10 fold increase in DNMT3AMut-HSCs and an activated inflammatory signaling. Cytokine analysis of BM fluid and BM derived adipocytes grown in vitro demonstrates an increased IL-6 levels under FBM conditions. Anti-IL-6 neutralizing antibodies significantly reduce the selective advantage of DNMT3AMut-HSCs exposed to FBM. Overall, paracrine FBM inflammatory signals promote DNMT3A-driven clonal hematopoiesis, which can be inhibited by blocking the IL-6 pathway.

16 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMArvind Singh Mer
Arvind Singh Mer
EHEmily M. Heath
Emily M. Heath
STSeyed Ali Madani Tonekaboni
Seyed Ali Madani Tonekaboni
NDNergiz Dogan-Artun
Nergiz Dogan-Artun
SNSisira Kadambat Nair
Sisira Kadambat Nair
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a distinct genetic entity in the revised World Health Organization classification. However, differing patterns of co-mutation and response to therapy within this group necessitate further stratification. Here we report two distinct subtypes within NPM1 mutated AML patients, which we label as primitive and committed based on the respective presence or absence of a stem cell signature. Using gene expression (RNA-seq), epigenomic (ATAC-seq) and immunophenotyping (CyToF) analysis, we associate each subtype with specific molecular characteristics, disease differentiation state and patient survival. Using ex vivo drug sensitivity profiling, we show a differential drug response of the subtypes to specific kinase inhibitors, irrespective of the FLT3-ITD status. Differential drug responses of the primitive and committed subtype are validated in an independent AML cohort. Our results highlight heterogeneity among NPM1 mutated AML patient samples based on stemness and suggest that the addition of kinase inhibitors to the treatment of cases with the primitive signature, lacking FLT3-ITD, could have therapeutic benefit.

23 June 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
ADAviv De-Morgan
Aviv De-Morgan
MMManja Meggendorfer
Manja Meggendorfer
CHClaudia Haferlach
Claudia Haferlach
LSLiran Shlush
Liran Shlush

28 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TFTzah Feldman
Tzah Feldman
ABAkhiad Bercovich
Akhiad Bercovich
YMYoni Moskovitz
Yoni Moskovitz
NCNoa Chapal-Ilani
Noa Chapal-Ilani
AMAmanda Mitchell
Amanda Mitchell
LSLiran I. Shlush
Liran I. Shlush
The mutational mechanisms underlying recurrent deletions in clonal hematopoiesis are not entirely clear. In the current study we inspect the genomic regions around recurrent deletions in myeloid malignancies, and identify microhomology-based signatures in CALR, ASXL1 and SRSF2 loci. We demonstrate that these deletions are the result of double stand break repair by a PARP1 dependent microhomology-mediated end joining (MMEJ) pathway. Importantly, we provide evidence that these recurrent deletions originate in pre-leukemic stem cells. While DNA polymerase theta (POLQ) is considered a key component in MMEJ repair, we provide evidence that pre-leukemic MMEJ (preL-MMEJ) deletions can be generated in POLQ knockout cells. In contrast, aphidicolin (an inhibitor of replicative polymerases and replication) treatment resulted in a significant reduction in preL-MMEJ. Altogether, our data indicate an association between POLQ independent MMEJ and clonal hematopoiesis and elucidate mutational mechanisms involved in the very first steps of leukemia evolution.

6 October 2015 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
LSLiran I. Shlush
Liran I. Shlush
SZSasan Zandi
Sasan Zandi
SIShalev Itzkovitz
Shalev Itzkovitz
ASAndre C. Schuh
Andre C. Schuh